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Abstract
Background: South Africa is home to the world’s largest antiretroviral therapy program but sustaining engagement
along the HIV care continuum has proven challenging in the country and throughout the wider region. Population
mobility is common in South Africa, but there are important research gaps in describing this mobility and its
impact on engagement in HIV care. Postpartum women and their infants in South Africa are known to be at high
risk of dropping out of HIV care after delivery and are frequently mobile.
Methods: In 2017, we developed a beta version of a smartphone application (app) - CareConekta - that detects a
user’s smartphone location to allow for prospective characterization of mobility. Now we will adapt and test
CareConekta to conduct essential formative work on mobility and evaluate an intervention - the CareConekta app
plus text notifications and phone calls and/or WhatsApp messages - to facilitate engagement in HIV care during
times of mobility. During the 3-year project period, our first objective is to evaluate the feasibility, acceptability, and
initial efficacy of using CareConekta as an intervention to improve engagement in HIV care. Our second objective is
to characterize mobility among South African women during the peripartum period and its impact on engagement
in HIV care. We will enroll 200 eligible pregnant women living with HIV and receiving care at the Gugulethu
Midwife Obstetric Unit in Cape Town, South Africa.
Discussion: This work will provide critical information about mobility during the peripartum period and the impact
on engagement in HIV care. Simultaneously, we will pilot test an intervention to improve engagement with
rigorously assessed outcomes. If successful, CareConekta offers tremendous potential as a research and service tool
that can be adapted and evaluated in multiple geographic regions, study contexts, and patient populations.
Trial registration: ClinicalTrials.gov: NCT03836625. Registered on 8 February 2019.
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Introduction
Background and rationale {6a}
With more than 7 million HIV-infected people [1],
South Africa is home to more people living with HIV
than any other country in the world [2], and their na-
tional antiretroviral therapy (ART) program is the
world’s largest [2]. South Africa adopted a “treat all” pol-
icy to provide ART to all HIV-positive people, regardless
of CD4+ cell count, in 2016 [3]. Expanded ART avail-
ability has dramatically altered the health and quality of
life of people living with HIV, with an estimated life ex-
pectancy gain of 11.3 years between 2003 and 2011 due
to ART [4] and a 77% decrease in HIV transmission in
stable serodiscordant couples [5]. However, the rapid
scale up of the national ART program has put tremen-
dous pressure on the limited resources of a public health
sector that is hurrying to meet this immense need, and
despite the widespread availability of ART, over 135,000
people died of AIDS-related causes in South Africa, ac-
cording to data published in 2018 [1]. HIV and tubercu-
losis (usually exacerbated by HIV) are the top two
causes of death among women ages 15–44 years in
South Africa [6]. The potential for improved health
through expanded ART availability will only be realized
if individuals sustain engagement in HIV care.
Black African women of reproductive age (ages 20–34
years) are the population most heavily affected by the
South African HIV epidemic, with 31.6% prevalence [7].
Expanded access to ART for all HIV-positive pregnant
women has helped to reduce mother-to-child transmis-
sion of HIV to the point where near-elimination is now
thought possible [8]. Despite this astounding achieve-
ment, there is mounting evidence that women who initi-
ate ART during pregnancy may be at very high risk of
loss to follow up (LTFU) [9–12], with re-engagement in
routine HIV care after delivery a particular concern [13,
14]. The problem of patient LTFU within the public sec-
tor in South Africa has been well-documented [15, 16].
Our earlier research conducted in South Africa found
that 25.2% of women pregnant at ART initiation were
LTFU after one year, compared to 15.8% of men and
11.1% of non-pregnant women [10]. LTFU is higher after
delivery than before: among women diagnosed with HIV
during antenatal care in Johannesburg, 47.9% were lost
within 6 months of delivery [13]; in Cape Town, disen-
gagement was over twice as frequent in the postpartum
period as during antenatal care [17].
A challenge to ensuring continuity of HIV care is that
the fragmented healthcare system is not adapted for a
mobile population. Patients considered LTFU actually
may have switched facilities on their own as “silent
transfers,” which typically are not recognized due to
unlinked data across facilities [18–20]. This
misclassification makes it very difficult to accurately
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assess the effectiveness of national ART programs.
Mobility as a potential barrier to engagement in HIV
care has been noted in Kenya [21, 22], Lesotho [23],
Zambia [24], and the USA [25]. South Africa’s
population is highly mobile; the most typical pattern is
of circular, within-border migration between rural and
urban areas, with the mobile individual keeping strong
ties to the rural areas by sending remittances to their
family and returning to the rural area for holidays and
family events, and upon retirement, illness, or during
lapses in employment [26]. Postpartum women in South
Africa are likely to be a particularly mobile group, due
to a tradition of returning to one’s rural home after de-
livery to receive care from family members [12, 27–29].
Our recent formative work at three sites in Johannes-
burg found that among 150 peripartum, HIV-positive
women interviewed, 44% planned to travel around deliv-
ery - typically after delivery - to stay with family, some-
times leaving the infant in the care of family while the
mother returned to work in Johannesburg [29]. With
unlinked medical records and no way of tracking mobil-
ity, it is difficult to intervene appropriately to ensure
continuity of HIV care for mother and infant.
Cell phones are as common in South Africa as they
are in the USA [30], according to a 2015 Pew
Research study that found that 89% of adults in
South Africa owned a cell phone [30]. Our own
research among pregnant, HIV-positive women at-
tending public antenatal care in Johannesburg found
that phone ownership was ubiquitous, phone sharing
was uncommon (94% did not share), and the median
time with the current phone number was 3 years
[31]. Additionally, smartphone use is increasing rap-
idly; a 2015 survey found that half of South African
respondents owned a smartphone [32]. While this
does not represent complete saturation, South Africa
is rapidly adopting increasingly sophisticated mobile
phones; thus, it is a very appropriate country in the
African region to develop and test mobile health
(mHealth) interventions, and lessons learned there
will be relevant throughout the continent as other
countries similarly adopt new technologies. mHealth
interventions, particularly short message service (SMS) in-
terventions, have been shown to improve adherence to
ART [33, 34] and patient retention [35, 36]. Global posi-
tioning system (GPS) technology has been used success-
fully to track subject location in several studies, mostly in
developed countries [37–39]. A few HIV-related studies
that used mobility-tracking wearable devices to assess mo-
bility have found acceptability and feasibility among young
men who have sex with men [40] and transgender women
[41] in the USA, demonstrating the relevance and utility
of mobility-tracking studies in other settings and
populations.
CareConekta is a novel smartphone app that uses GPS
to identify the user’s location coordinates to meet two
primary functions: (1) observe mobility prospectively,
and (2) to allow the participant to locate nearby ART
facilities using current location and a pre-loaded list of
health facilities in South Africa, searchable through Goo-
gle Maps. The app was devised by the study investigators
(Drs Clouse, Phillips, and Myer) in parallel with a series
of focus group discussions with potential users, devel-
oped as a beta version at Vanderbilt University Medical
Center by Dr Martin Were and team, and then redeve-
loped and adapted by Jembi Health Systems in Cape
Town. Regular “heartbeat” signals from the phone’s GPS
system provides the participant’s current location geo-
coordinates, which are made “fuzzy” by transmitting a
random location within one kilometer (km) of each
exact location to protect privacy. Data charges related to
the app are reverse-billed to the study, so that partici-
pants do not pay extra for cellular data. Knowledge of
traveling participants allows the investigators to inter-
vene in real time; thus, if the participant in the interven-
tion arm travels more than 50 km outside the study area
for more than 7 days, the app will automatically notify
the participant of available care facilities near her new
location. Additionally, study staff may contact the travel-
ing participants through phone calls and/or WhatsApp
to assist in linkage to care.
Through this 3-year study, we seek to assess the feasi-
bility, acceptability and initial efficacy of using CareCo-
nekta to improve engagement in HIV care among
postpartum women in South Africa.
Objectives {7}
Aim 1
Aim 1 is to characterize mobility among South African
women during the peripartum period and its impact on
engagement in HIV care.
Aim 1a
Aim 1a it to use GPS location data from CareConekta
and spatial analysis to characterize peripartum mobility
within the complete observational cohort (n = 200),
including the frequency, distance, and timing.
Aim 1b
Aim 2b is to assess the association between mobility and
engagement in HIV care for mother (retention in care
and viral suppression 6 months after delivery) and infant
(completion of routine early infant diagnosis).
Aim 2
Aim 2 is to evaluate enhanced CareConekta as an
intervention to improve engagement in HIV care.
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Aim 2a
Aim 2a is to assess the acceptability and feasibility of the
standard and enhanced app, with a focus on identifying
user preference and implementation outcomes.
Aim 2b
Aim 2b is to evaluate the initial efficacy of the enhanced
CareConekta intervention, using notifications and staff
contact to improve engagement in HIV care, by
assessing the association between study arm and
engagement in HIV care at 6 months postpartum.
Trial design {8}
This is a single-center, open-label, parallel-arm, random-
ized controlled trial to assess the feasibility, acceptability,
and initial efficacy of using a novel smartphone applica-
tion to improve engagement in postpartum HIV care in
South Africa.
Methods: Participants, interventions and
outcomes
Study setting {9}
The study site for participant enrollment is the
Gugulethu Midwife Obstetric Unit (MOU), based at the
Gugulethu Community Health Center near Cape Town,
South Africa. The MOU serves Gugulethu as well as the
surrounding informal settlements, and is often attended
by women who come from the Eastern Cape to have
their babies in Cape Town, resulting in travel to and
from the Eastern Cape during pregnancy and
postpartum [42]. The local antenatal HIV prevalence is
high (~ 30%), and the mother-to-child HIV transmission
rate is estimated at 2–4% [43]. The MOU team has
helped to deliver HIV care and treatment services in this
setting since 2003 and has a history of successful ART
service delivery and research in partnership with the
provincial government. Members of the study team have
conducted studies at the MOU since 2006 [44].
Eligibility criteria {10}
Eligible subjects are adult (≥ 18 years) women living with
HIV who are in the third trimester of pregnancy (≥ 28
weeks gestation) and are willing to be randomized.
Subjects must be able to speak and understand isiXhosa
and/or English. Basic smartphone-level literacy must be
demonstrated by asking the participant to read aloud the
following sentence in either English or isiXhosa: “I can
look up a new clinic on the phone.” Last, eligible partici-
pants must currently own a smartphone that meets the
technical requirements of the app and be willing to opt
in to installation of the app on her personal phone and
to agree to mobility tracking. The specific technical re-
quirements of the app include (1) a touchscreen, (2) cap-
able of accessing the Internet, (3) operating system
Android, version 5.0 or later, (4) cellular service is pro-
vided by one of the four major networks in South Africa
(Cell-C, MTN, Telkom, or Vodacom), (5) capable of
using GPS to show current location, and (6) requires
charging the battery less than twice a day, on average. In
our preliminary work, nearly 90% of smartphones of
women approached for study participation used the An-
droid system [45].
Late pregnancy was selected in order to allow for a 9-
month total follow-up time within the time constraints
of a 3-year project. In South Africa, most women present
for their first antenatal visit around 20 weeks gestation
or later [13, 46, 47], and attendance for antenatal visits is
generally high [13, 17], so we do not believe there will
be substantial bias introduced by enrolling women later
in pregnancy. isiXhosa is the predominant language in
the region of the study site, and English also is widely
spoken, so we do not anticipate excluding potential par-
ticipants due to language. Basic smartphone-level liter-
acy will be required of participants in order to assess the
impact of messages. However, we anticipate that most
women who own a smartphone already have a basic
level of smartphone literacy. We acknowledge that
women who own a smartphone may be different to
those who do not, in terms of employment, education,
or other factors.
Who will take informed consent? {26a}
Written informed consent is obtained by a study team
member fluent in isiXhosa and English who has
completed Human Subjects Protections and Good
Clinical Practice certification. All women who meet the
eligibility criteria and are interested in participating in
the study will undergo written informed consent, which
will be available in English and isiXhosa. The consent
form will confirm the eligible woman’s understanding of
the study procedures and her informed willingness to
participate. The key messages of the informed consent
process will include (1) a description of the study goals
and procedures, (2) voluntary participation in the study,
(3) confidentiality and privacy with use of the app and
study data, (4) the right to withdraw at any time, and (5)
the standard of care received at the MOU or any other
healthcare facility will not differ according to
participation in the study.
Once the consent form has been explained to the
participant, any questions she may have will be
answered. If the participant agrees to provide consent
for participation, she will indicate this with her signature
on the consent form. If she does not wish to participate
or does not provide her consent for all the activities, she
will not sign the consent form and will not be enrolled.
A second copy of the form will be provided for her to
sign and keep, if requested. The study staff member who
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administered the form will provide his or her name,
signature, and date as a witness to the signing. Signed
informed consent forms will be stored in binders within
a locked office and only accessible by study staff.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
The informed consent form specifically requests
permission for installation of the app, location tracking,
data collection, medical record review (participant and
infant), one blood draw, and re-contact by study staff.
Interventions
Explanation for the choice of comparators {6b}
In order to assess CareConekta’s ability to track
participant location, the CareConekta app will be
installed for all study participants - regardless of study
arm. This also will allow all participants to passively
search for new clinics using the facility finder. To assess
the potential of using real-time location data in order to
improve engagement in HIV care, participants in the
intervention arm will receive enhanced follow up when
they travel.
Intervention description {11a}
Participants in the control arm (n = 100) will receive
standard CareConekta, which will track their mobility
and allow the participant to look up new ART facilities
upon request. Participants in the intervention arm (n =
100) also will receive standard CareConekta with the
following additions:
 Push notifications prompting the participant to open
the app to view nearby ART facilities when they
have traveled > 50 km from the study site for > 7
days.
 Phone call(s) and/or WhatsApp message(s) from
study staff when they have traveled > 50 km from
the study site for > 7 days. The study-staff calls and
messages will ask about medication supply and will
provide assistance with nearby facilities, if requested.
Criteria for discontinuing or modifying allocated
interventions {11b}
The additional communication included in the
intervention arm will be discontinued at the participant’s
request.
Strategies to improve adherence to interventions {11c}
The intervention will be delivered only if the participant
has met the travel threshold described above. No
additional participant behavior is required in order to
receive the intervention. To ensure staff fidelity of the
intervention, push notifications are standardized, and a
brief script has been developed (in English and isiXhosa)
for items to be addressed in the phone calls and/or
WhatsApp messages to participants. If app “heartbeats”
are not received, participants will be contacted to
troubleshoot technical problems, regardless of study
arm.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Subjects are ineligible for study participation if they are
currently involved in another research study that may
impact the study outcomes. Routine clinical care will
continue as usual for all participants.
Provisions for post-trial care {30}
During and after the trial, participants will continue to
receive routine care at the clinic of their choice.
Outcomes {12}
This study will collect data by the following three
methods:
 GPS location (mobility) data collected through the
CareConekta app
 Participant responses to questionnaires at the
enrollment and follow-up visits, and during a brief
postpartum interim phone call
 Post-study review of participant electronic and
paper medical records
Primary outcome: Mobility within the study period
We will use data from all 200 participants to describe
mobility within a complete observational cohort. In
order to assess mobility comprehensively, we will use
multiple data sources: time and date-stamp data and
geographic location data from CareConekta, participant
self-report during questionnaires, and electronic medical
records during the file review.
Secondary outcome 1: Impact of mobility on engagement
in HIV care in the absence of the intervention
Limiting the analysis to only the 100 participants in the
control arm, we will explore the impact of mobility on
engagement in HIV care in the absence of intervention
by using GPS location data and engagement in HIV care
data retrieved through medical record review. To assess
engagement in HIV care, we will report retention in
care, which will be assessed at the 6-month postpartum
point and defined as no documented HIV-specific con-
tact with any healthcare facility (including medication
pick-ups) for > 3 months. We also will report viral sup-
pression 6 months after delivery based on the viral load
test closest to the 6-month period, using thresholds of ≤
50 and ≤ 1000 copies/ml. Additionally, we will report
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vertical HIV transmission and completion of the routine
10-week infant polymerase chain reaction (PCR) test.
Secondary outcome 2: Acceptability and feasibility of
CareConekta
Acceptability and feasibility data will be collected among
all 200 participants. Those in the intervention arm will
receive additional questions related to the enhanced app
features. The outcomes selected for analysis correspond
with the Technology Acceptance Model for Resource-
Limited Settings (TAM-RLS) framework, which was de-
signed to draw attention to end-user acceptability as a
predictor of mHealth technology adoption in low-
resource settings [48].
Secondary outcome 3: Initial efficacy of the intervention
The overall efficacy analysis will include participants in
both arms (n = 200). Engagement in HIV care will be
defined as for the measure in “Secondary outcome 1”.




We will enroll 200 participants in total. Sample size was
not formally estimated for this pilot trial. The sample
size was reached based on the feasible enrollment from
the study site within the study timeline. Approximately
4000 women seek antenatal care at the MOU annually;
~ 30% of these are HIV-positive, about 1200 per year, or
100 per month. Our formative work at the study site
showed that over half of these women own smartphones.
If we conservatively estimate that 30% of all pregnant,
HIV-positive women seeking antenatal care each month
will be eligible and interested, this equals 30 participants
enrolled per month. We anticipate that it will take ap-
proximately 7 months to reach our enrollment target of
200 participants.
Recruitment {15}
Each week during the study recruitment period, study
staff will review the list of upcoming appointments at
the study site to assess who may be eligible for study
participation. Pregnant women attending routine ante-
natal care services at the Gugulethu Community Health
Center will be approached by trained study recruiters
and given brief information about the pilot study. If they
are interested, they will be screened to ensure they meet
the eligibility criteria, using an eligibility checklist. If eli-
gible, they also will be shown a demonstration of Care-
Conekta and its functionality prior to the informed
consent process.
Assignment of interventions: allocation
Sequence generation {16a}
The randomization sequence will be generated in R with
a 1:1 allocation ratio within randomly permuted blocks
to ensure balanced allocation to the intervention and
control arms.
Concealment mechanism {16b}
Randomization assignment will be concealed in sequen-
tially numbered, opaque sealed envelopes until opened
after enrollment with the participant.
Implementation {16c}
The sequence will be generated by a statistician inde-
pendent of the study team. The randomization assign-
ment envelopes will be created by an individual at the
University of Cape Town independent of the study team
following the generated sequence. After enrolling a par-
ticipant, the site staff will select the next consecutive
sealed envelope to reveal study arm assignment.
Assignment of interventions: Blinding
Who will be blinded {17a}
Due to the open-label nature of this study, no blinding
will be used.
Procedure for unblinding if needed {17b}
Due to the open-label nature of this study, no blinding
will be used.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Mobility data will be collected throughout the study
using the GPS tracking feature of the CareConekta app.
For recording participant characteristics, several study
measures have been used previously by the study investi-
gators in similar populations at the study site and in
other areas of South Africa. In addition, we are using the
following widely used, validated measurement scales:
 ART adherence: 3-item self-report measure (Wilson,
et al.) [49]
 Alcohol use: Alcohol Use Disorders Identification
Test-Concise (AUDIT-C) [50]
 Drugs: Question 1 from Drug Use Disorders
Identification Test (DUDIT) [51]
 Depression: Patient Health Questionnaire-4 (PHQ-4)
[52]
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 Intimate partner violence: World Health
Organization Violence Against Women (WHO
VAW) measurement [53]
 Life events [54]
 Patient-healthcare provider relationship [55]
 Perceived availability of support [56]
 Social impact scale [57]
Study forms are available by request to the
investigators.
Plans to promote participant retention and complete
follow up {18b}
In order to maximize the potential of re-contacting each
participant and accessing medical records, we will collect
identifying information on a separate paper-based link-
age form, including contact information, name, study
number, clinic record number, phone number, national
identification number, address, and date of birth, and we
will also update this form with infant information, when
available. As is standard practice for research studies at
the study site, the participant may also provide details
for an alternative contact person in the event that we are
unable to reach the participant after multiple attempts.
No details about the participant will be shared with the
alternative contact; study staff simply will ask that the
participant return to the clinic when she can. For the in-
terim phone call and follow-up visit, a minimum of three
contact attempts by phone and/or home visit will be
made for each participant. If participant mobility data
cease to transmit at least once per day, the study team
will follow up with the participant to find out if there
are problems with her phone.
Data management {19}
All hard copies of study documents, including signed
consent forms, linkage forms, and logs, will be stored in
locked cabinets in the study office with only the study
team having access to the data. For increased protection,
the linkage form and signed consent forms will be stored
separately from other study documents.
Enrollment and follow-up questionnaires are designed
in Research Electronic Data Capture (REDCap) and will
be administered electronically using the REDCap mobile
app. REDCap is a secure, web-based application de-
signed to support data capture for research studies, pro-
viding (1) an intuitive interface for validated data entry;
(2) audit trails for tracking data manipulation and export
procedures; (3) automated export procedures for seam-
less data downloads to common statistical packages; and
(4) procedures for importing data from external sources
[58]. Range checks for numerical values and prompts
about skipped questions are built into the REDCap data-
base. The data will be collected with the study
interviewer/fieldworker - who is fluent in isiXhosa and
English - during a face-to-face interaction with the par-
ticipant. The study coordinator will review all participant
data to ensure completion. The Principal Investigator
(PI) also will monitor the study safety data on an on-
going basis. The encrypted REDCap data servers will be
housed at Vanderbilt University Medical Center. Partici-
pant questionnaire data and medical record data will be
exported from REDCap, and mobility data from CareCo-
nekta will be imported from .csv files to SAS for data
analysis.
The transmission and storage of sensitive participant
information will follow best practices regarding smart-
phone app confidentiality. All information collected by
CareConekta, including location, device ID, and time
stamp, will be encrypted and transmitted to secure study
servers using the secure https protocol. Time-stamped
GPS coordinates will be stored in a longitudinal history.
Electronic mobility data will be stored on a back-end
storage system at the South African Medical Research
Council (MRC) that meets Health Normative Standards
Framework guidelines, which call for restricted access,
and the separation of patient demographics and health
data. The user reference (unique ID or demographic in-
formation of the patient) is separated from the user’s cell
number and phone ID, as well as separated from the lo-
cation information for security and purposes.
Confidentiality {27}
Certainly, the concept of tracing an individual’s personal
location is one that must address substantial protections
of human subjects. First, our formative research with po-
tential users in focus group discussions specifically ad-
dressed issues of privacy regarding a mobility-tracing
app and notifications. For both issues, we found high ac-
ceptability [59].
While we feel that our formative research clearly in-
dicates initial acceptability of mobility tracing and no-
tifications, we have designed this work with a strong
commitment to offering the highest level of protec-
tion of our participants’ privacy and confidentiality.
First, the location data of interest are at the macro-
level, showing movement between towns, cities, or re-
gions, not at the micro-level, showing specific where-
abouts. Thus, to protect participants’ privacy, the
transmitted location information will be made “fuzzy”
by transmitting a random location within 1 km of
each participant’s exact location. Any participant’s
exact location within that radius will be unknown. All
information collected by the app, including location,
device ID, and time stamp, will be transmitted to se-
cure study servers using the secure https protocol.
The participant’s numerical study ID number will be
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used during installation; no identifiable participant in-
formation will be recorded in the app.
There is always the possibility of a breach of confi-
dentiality of study materials when conducting re-
search. While this is acknowledged, there is very low
likelihood because of the precautions that will be
taken to protect confidentiality. Study staff will be
trained on the expectations that they are not to dis-
close any information collected in the study to any-
one outside the study team. All identifying
information associated with the study participants
will be maintained in locked storage cabinets and
password-protected computers that themselves are
kept in locked rooms or cabinets. All participants
will be encouraged to contact the clinic staff, PIs, or
other staff to report any undesirable conduct associ-
ated with the study. These reports will be brought to
the attention of the PI.
Another risk to participants is that an HIV-positive
status may be discerned through disclosure of par-
ticipation in the study. However, we will do every-
thing possible to minimize the risk of disclosure. No
communication, whether on the phone or by text
message, will identify the participant as HIV-positive.
Importantly, among participants in the intervention
arm who receive notifications of new facilities and
phone calls and/or WhatsApp messages, the study
staff will not use HIV-specific language. To avoid
the possibility of inadvertent disclosure, ART facil-
ities will only be referred to generically as “clinics”
and any reference to ART will be to “tablets,” a
common term for any medication that we demon-
strated was acceptable in an earlier mHealth study
in South Africa [46].
Risk to subjects will be minimized by (1) training re-
search staff in the ethical conduct of research; (2) strict
protection of confidentiality by detailed standard operat-
ing procedures and on-site monitoring; (3) careful hand-
ling of sensitive data, procedures, and processes in place
to ensure data is securely stored and transferred; and
(4) referral of participants to appropriate social and
health services when necessary. The study site is well-
connected with the social worker and psychology ser-
vices at the site and with local non-governmental or-
ganizations providing counseling and support. While
the potential risks to subjects are low, any social
harm will be reported to the PI and a serious event
will be reported to the Vanderbilt University and
University of Cape Town Institutional Review Boards
(IRBs) within 48 h of becoming aware of the event.
Should any respondent experience discomfort or dis-
tress from participation in the study, we will provide
the participant with the appropriate referral needed
for follow up and care.
Risk to subjects from participation in the study is min-
imal. All possible precautions will be taken to ensure
complete confidentiality and protection of study partici-
pants. Given the minimal risk, the overall benefit of the
study outweighs the risks.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
We will not collect blood or other biological specimens
during this study. In routine care in this setting, viral
load tests are to be repeated every 3 months in preg-
nancy and every 6 months during breastfeeding, so we
expect that most women will have a routine viral load
completed before 6 months postpartum. To avoid add-
itional blood draws for the participant, at the follow-up
visit, the study staff will check electronic health records
to determine the most recent viral load test. If the par-
ticipant has had no viral load test within 3 months prior
to the 6-month study follow-up visit, she will be referred
for a blood draw for routine viral load testing at the
clinic. Study staff will not conduct the blood draw and
blood will not be stored.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Primary outcome: Mobility within the study period
To assess the primary outcome of interest, we will report
the number of participants who travel during the study
period (defined as > 50 km for > 7 days), over the denom-
inator of all participants. Among those who travel, we
will report the median and interquartile range number
of trips during the study period and will determine tim-
ing and frequency of travel as it relates to delivery date,
which will be obtained from the participant question-
naire and/or medical records. Median and interquartile
range for duration of travel will be reported in days, and
we will also assess temporicity (frequency of trips * dur-
ation of trips). Reasons for travel will be obtained from
the enrollment and follow-up questionnaire and will be
grouped by theme, such as family, work, housing, and
education.
For a more detailed assessment of mobility, we will
use ArcMap to geographically place all locations in
which participants were recorded during the study
period. We will plot origin and destination locations on
a map of South Africa, and neighboring countries (if ne-
cessary). We will connect origin and destination loca-
tions using ArcMap’s XY-to-line tool, and will use a
spherical calculator to estimate the distance between ori-
gin and destination. The geographic data will be used in
conjunction with the novel metrics of mobility devel-
oped by Dr Camlin, which are reflective of the complex
Clouse et al. Trials          (2020) 21:258 Page 8 of 12
forms of mobility in sub-Saharan Africa. For example,
we will apply geopolitical boundaries to location codes
so that measures of internal migration and localized mo-
bility within and across those boundaries can be esti-
mated, such as inter-provincial and intra-provincial
mobility. We also will map mobility flow according to
origin and destination pairs, classified by geopolitical
categories. We will thereby demonstrate how geographic
data can be used to characterize the mobility of popula-
tions - providing a vital alternative to survey measures -
in order to measure the impacts of that mobility on care
cascade outcomes, with broad applicability to the meas-
urement of its impact on other health outcomes. We
also will conduct a secondary analysis to validate
whether self-reported anticipated travel matches data
collected from the CareConekta app.
Secondary outcome 1: Impact of mobility on engagement
in HIV care in the absence of the intervention
We will limit the analysis to the control arm only, to ex-
plore the impact of mobility on engagement in HIV care
in the absence of intervention. We will report baseline
participant characteristics as collected on the enrollment
questionnaire. We will report proportions and 95% con-
fidence intervals for categorical variables and medians
and interquartile ranges for continuous variables.
To assess engagement in HIV care, we will report re-
tention in care, which will be assessed at the 6-month
postpartum point and defined as no documented HIV-
specific contact with any healthcare facility (including
medication pick-ups) for > 3months. We also will report
viral suppression 6 months after delivery, using thresh-
olds of ≤ 50 and ≤ 1000 copies/ml. Additionally, we will
report vertical HIV transmission and completion of the
routine 10-week infant PCR test.
We will fit a series of models of mobility metrics on out-
comes. For one, we will use a dichotomous exposure of
mobility (any travel > 50 km: yes/no), we will use Cox pro-
portional hazard regression models to estimate the associ-
ation of mobility on these outcomes, and will produce
adjusted hazard ratios and 95% confidence intervals for re-
tention in care and achieving viral suppression. We also
will identify other predictors of engagement in HIV care.
We will produce crude Kaplan-Meier curves for time to
loss to follow up and time to viral suppression, by mobility
group. Additionally, we will perform sensitivity analyses to
explore how the estimated effect size changes when using
varying cutoff points to define mobility.
Secondary outcome 2: Acceptability and feasibility of
CareConekta
We will report proportions and 95% confidence intervals
for categorical variables and medians and interquartile
ranges for continuous variables. Open-ended questions
will be reviewed for key themes. Themes will be ab-
stracted and quantified.
Secondary outcome 3: Initial efficacy of the intervention
We will use Cox proportional hazard regression models
to estimate the association of study arm assignment with
these outcomes, and will produce adjusted hazard ratios
and 95% confidence intervals for retention in care and
achieving viral suppression, by study arm. We also will
identify other predictors of engagement in HIV care. We
will produce crude Kaplan-Meier curves for time to loss
to follow up and time to viral suppression by study arm.
In a secondary analysis, we will perform an as-treated
analysis using self-reported data on actually reading the
notifications and/or WhatsApp messages or staff phone
calls, to analyze the effect of receiving the intervention.
Interim analyses {21b}
No interim analyses are anticipated, and no stopping
guidelines have been established, due to the low risk of
participant harm during this study.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Anticipated analyses are as described above.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
The primary study analysis will be an intention-to-treat
analysis based on actual random allocations. Secondary
per-protocol analyses will be performed if there has been
protocol non-adherence.
The nature of missing data will be assessed and, where
appropriate, sensitivity analyses will be conducted using
multiple imputation.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
This study is registered on ClinicalTrials.gov
(NCT03836625), so the protocol is publicly available.
De-identified participant-level data and statistical code
will be available by request of the study investigators.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
Due to the relatively small nature of the study team,
additional coordinating centers and committees will not
be convened.
Composition of the data monitoring committee, its role
and reporting structure {21a}
As this is a pilot study, a data safety and monitoring
committee is not required and will not be convened.
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Adverse event reporting and harms {22}
We anticipate that the potential for adverse events (AEs)
and serious adverse events (SAEs) related to study par-
ticipation is low. However, we will document, investi-
gate, and follow up all potentially study-related AEs, in
accordance with IRB guidelines and sponsor policies. All
reports will be made in writing to the study sponsor pro-
gram officer.
Additionally, there is always the potential for social
harms to participants of clinical trials, particularly when
the clinical trial is limited to individuals with HIV. Any
social harm will be reported to the PI and considered an
AE and/or SAE and reported according to the aforemen-
tioned schedule. Should any respondent experience dis-
comfort or distress from participation in the study, we
will provide the participant with the appropriate referral
needed for follow up and care.
Frequency and plans for auditing trial conduct {23}
Study data and procedures will be regularly reviewed by
the study team. No formal study audits are planned.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
In the unlikely event that we must revise our consent
form to reflect changes to the study protocol, study staff
will re-contact participants to bring them back to the
clinic to be re-consented. Home visits will be made, if
necessary. The public study record available on Clinical-
Trials.gov also will be updated at the time of IRB ap-
proval of the new documents.
Dissemination plans {31a}
We anticipate numerous manuscripts resulting from this
study. Manuscripts will be written by members of the
study team, and we will also welcome predoctoral and
postdoctoral trainees affiliated with our institutions to
lead secondary manuscripts to facilitate capacity build-
ing. Study results will also be shared at national and
international HIV meetings and with the municipal, pro-
vincial, and national departments of health in South
Africa.
Discussion
Engagement in HIV care through the pregnancy and
postpartum period is a substantial challenge to the suc-
cess of the South African national ART program, as well
as other countries in the region. This innovative study
seeks to provide critical information to understand mo-
bility during a specific, limited time period and to assess
the potential impact of mobility on engagement in HIV
care, while also providing a novel tool for improving
engagement.
This study is among the first to track participant mo-
bility in real time and use that information to intervene
to improve engagement in HIV care. Collecting and
using participant location information through smart-
phones is not without critics. Beginning with our forma-
tive research, we have closely considered user privacy. In
focus group discussions, after first describing mobility
tracking, we explicitly asked, “What do you think about
a cell phone recording location so that researchers can
use it? Would you want to do this?” and found high ac-
ceptability [59]. Most commercial smartphone apps col-
lect a host of user data, often including GPS data; in our
case, we want the potential user to make an informed
decision to enroll, to safeguard the data as much as pos-
sible, and to use the data to address critical gaps in re-
search about engagement in HIV care.
This study will provide considerable practical infor-
mation about the feasibility of implementing
smartphone-based applications in a resource-limited
setting. We acknowledge that women who own a
smartphone may be different to those who do not, in
terms of employment, education, or other factors. Be-
sides the additional financial resources needed to pro-
vide phones, we want to be able to assess
CareConekta in existing phones for maximal impact.
If women already have a smartphone (estimated at
over half of the population), providing a second
phone for study purposes is redundant and burden-
some. For women who do not already own a smart-
phone, we are concerned with the ethical implications
of providing such a highly desired item as a smart-
phone in terms of possible coercion for study partici-
pation, the impact it may have on relationships
between participants and partners and/or friends, and
the potential for disclosure for participating in an
HIV-related study.
Our study represents a participant population accessing
care at one research site only. The proposed site is long-
established as a qualified research site under the direction
of our co-investigators. Engagement in postpartum HIV
care is a problem among the patient population, as similarly
demonstrated in studies throughout South Africa, and
women are known to travel during the peripartum period,
most frequently to the Eastern Cape Province of South Af-
rica. We believe that the study site and the population it
serves is representative of other public antenatal clinics in
peri-urban South Africa.
If we are successful in demonstrating the feasibility, ac-
ceptability, and initial efficacy of CareConekta, our goal is
to assess it in a larger randomized, controlled trial in differ-
ent regions. CareConekta offers tremendous potential as a
research and service tool and can be adapted and evaluated
in multiple geographic regions, study contexts, and patient
populations.
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Trial status
This is protocol Version 4.0; dated 18 November 2019.
Enrollment began on 9 December 2019 and will con-
tinue approximately through 30 June 2020.
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